Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market
06:46pm, Wednesday, 28'th Feb 2024
Biogen Inc. (BIIB) concluded the recent trading session at $221.74, signifying a -0.98% move from its prior day's close.
EU medicines regulator backs Biogen's ALS drug
06:16am, Friday, 23'rd Feb 2024
Europe's medicines regulator said on Friday that it has recommended granting a marketing authorization for Biogen's drug for a type of neurological disease known as amyotrophic lateral sclerosis (ALS)
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
01:46pm, Monday, 19'th Feb 2024
Stock turnarounds can happen when you least expect it. And with the opposite scenario imposing a rude awakening, it's time to at least consider last year's losers to make big splashes in 2024.
Where Are Biotech ETFs Headed After Q4 Earnings?
05:51pm, Wednesday, 14'th Feb 2024
Look into how Biotech ETFs performed after Q4 earnings.
Biogen receives subpoena from DOJ on business operations in foreign countries
06:19am, Wednesday, 14'th Feb 2024
Biogen has received a subpoena from the U.S. Department of Justice seeking information relating to the company's business operations in several foreign countries, the drugmaker disclosed in a filing o
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
12:21pm, Tuesday, 13'th Feb 2024
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
10:36am, Tuesday, 13'th Feb 2024
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street e
Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates
09:21am, Tuesday, 13'th Feb 2024
Biogen Inc. (BIIB) came out with quarterly earnings of $2.95 per share, missing the Zacks Consensus Estimate of $3.16 per share. This compares to earnings of $4.05 per share a year ago.
Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
07:21am, Tuesday, 13'th Feb 2024
Biogen Inc. BIIB, +1.56% on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
07:03am, Tuesday, 13'th Feb 2024
The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
Biogen's rare genetic disorder drug gets approval in EU
04:21pm, Monday, 12'th Feb 2024
Biogen said on Monday the European Commission has approved its drug for treating a rare genetic disorder that causes progressive damage to the nervous system, in adults and adolescents aged 16 years a
Wall Street Brunch: Retail Inflation In Focus
11:23am, Sunday, 11'th Feb 2024
This week, traders will have a lot of economic data to digest, including retail sales, manufacturing measures, jobless claims, and the consumer price index. The market is now pricing in a 16% chance o
Biogen Inc. (BIIB) Stock Sinks As Market Gains: Here's Why
06:51pm, Thursday, 08'th Feb 2024
In the most recent trading session, Biogen Inc. (BIIB) closed at $240.30, indicating a -0.1% shift from the previous trading day.
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
11:35am, Thursday, 08'th Feb 2024
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
